image
Healthcare - Medical - Devices - NASDAQ - US
$ 7.61
-0.262 %
$ 474 M
Market Cap
-7.69
P/E
1. INTRINSIC VALUE

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.[ Read More ]

The intrinsic value of one TMCI stock under the base case scenario is HIDDEN Compared to the current market price of 7.61 USD, Treace Medical Concepts, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TMCI

image
FINANCIALS
187 M REVENUE
31.92%
-51.4 M OPERATING INCOME
-47.59%
-49.5 M NET INCOME
-15.68%
-34.6 M OPERATING CASH FLOW
-12.81%
-81.3 M INVESTING CASH FLOW
-6.25%
109 M FINANCING CASH FLOW
425.73%
45.1 M REVENUE
1.42%
-15.1 M OPERATING INCOME
29.22%
-15.4 M NET INCOME
27.57%
-11.8 M OPERATING CASH FLOW
14.79%
5.76 M INVESTING CASH FLOW
-74.31%
8 K FINANCING CASH FLOW
-97.43%
Balance Sheet Decomposition Treace Medical Concepts, Inc.
image
Current Assets 198 M
Cash & Short-Term Investments 123 M
Receivables 38.1 M
Other Current Assets 37.1 M
Non-Current Assets 53.5 M
Long-Term Investments 0
PP&E 31.6 M
Other Non-Current Assets 22 M
Current Liabilities 45 M
Accounts Payable 11.8 M
Short-Term Debt 1.4 M
Other Current Liabilities 31.8 M
Non-Current Liabilities 68.9 M
Long-Term Debt 68.9 M
Other Non-Current Liabilities 37 K
EFFICIENCY
Earnings Waterfall Treace Medical Concepts, Inc.
image
Revenue 187 M
Cost Of Revenue 35.2 M
Gross Profit 152 M
Operating Expenses 203 M
Operating Income -51.4 M
Other Expenses -1.9 M
Net Income -49.5 M
RATIOS
81.20% GROSS MARGIN
81.20%
-27.48% OPERATING MARGIN
-27.48%
-26.47% NET MARGIN
-26.47%
-35.91% ROE
-35.91%
-19.66% ROA
-19.66%
-26.93% ROIC
-26.93%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Treace Medical Concepts, Inc.
image
Net Income -49.5 M
Depreciation & Amortization 5.35 M
Capital Expenditures -11.5 M
Stock-Based Compensation 17.4 M
Change in Working Capital -9.74 M
Others 8.23 M
Free Cash Flow -46 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Treace Medical Concepts, Inc.
image
Wall Street analysts predict an average 1-year price target for TMCI of $17.8 , with forecasts ranging from a low of $6.5 to a high of $28 .
TMCI Lowest Price Target Wall Street Target
6.5 USD -14.59%
TMCI Average Price Target Wall Street Target
17.8 USD 133.90%
TMCI Highest Price Target Wall Street Target
28 USD 267.94%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Treace Medical Concepts, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
266 K USD 1
0-3 MONTHS
2.52 M USD 3
3-6 MONTHS
4.52 M USD 6
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Sep 16, 2024
Bought 266 K USD
Treace John T.
Chief Executive Officer
+ 50000
5.3126 USD
3 months ago
Aug 15, 2024
Bought 501 K USD
TREACE JAMES T
Director
+ 84000
5.9647 USD
3 months ago
Aug 14, 2024
Bought 510 K USD
Treace John T.
Chief Executive Officer
+ 85000
6.0037 USD
5 months ago
Jun 11, 2024
Bought 265 K USD
Treace John T.
Chief Executive Officer
+ 45000
5.88 USD
5 months ago
May 31, 2024
Bought 151 K USD
TREACE JAMES T
Director
+ 25000
6.0531 USD
5 months ago
May 29, 2024
Bought 130 K USD
TREACE JAMES T
Director
+ 25000
5.2025 USD
5 months ago
May 28, 2024
Bought 253 K USD
TREACE JAMES T
Director
+ 50000
5.0695 USD
5 months ago
May 24, 2024
Bought 93.5 K USD
MOTT RICHARD W
Director
+ 18000
5.1945 USD
5 months ago
May 22, 2024
Bought 60.4 K USD
MOTT RICHARD W
Director
+ 12100
4.9938 USD
6 months ago
May 17, 2024
Bought 556 K USD
Treace John T.
Chief Executive Officer
+ 100000
5.5617 USD
6 months ago
May 14, 2024
Bought 100 K USD
Kiernan Jane E
Director
+ 19356
5.1664 USD
6 months ago
May 14, 2024
Bought 768 K USD
Treace John T.
Chief Executive Officer
+ 150000
5.1187 USD
6 months ago
May 10, 2024
Bought 113 K USD
Jain Deepti
Director
+ 25000
4.5027 USD
6 months ago
May 13, 2024
Bought 161 K USD
MOTT RICHARD W
Director
+ 36802
4.3772 USD
6 months ago
May 10, 2024
Bought 380 K USD
MOTT RICHARD W
Director
+ 83198
4.5656 USD
6 months ago
May 13, 2024
Bought 658 K USD
TREACE JAMES T
Director
+ 145000
4.5378 USD
6 months ago
May 10, 2024
Bought 376 K USD
TREACE JAMES T
Director
+ 83000
4.5304 USD
6 months ago
May 10, 2024
Bought 595 K USD
BAKEWELL JOHN K
Director
+ 130000
4.574 USD
6 months ago
May 13, 2024
Bought 683 K USD
Treace John T.
Chief Executive Officer
+ 150000
4.5566 USD
6 months ago
May 10, 2024
Bought 687 K USD
Treace John T.
Chief Executive Officer
+ 150000
4.5792 USD
2 years ago
Nov 15, 2022
Sell 936 K USD
TREACE JAMES T
Director
- 46500
20.12 USD
2 years ago
Nov 15, 2022
Sell 33.9 K USD
TREACE JAMES T
Director
- 1600
21.1813 USD
2 years ago
Nov 15, 2022
Sell 4.39 K USD
TREACE JAMES T
Director
- 200
21.97 USD
2 years ago
Nov 15, 2022
Sell 40.8 K USD
TREACE JAMES T
Director
- 1700
24.0167 USD
1 year ago
Jun 02, 2023
Sell 1.29 M USD
BAYS F BARRY
- 48503
26.51 USD
1 year ago
Jun 05, 2023
Sell 27.6 M USD
BAYS F BARRY
- 1042318
26.51 USD
1 year ago
May 16, 2023
Sell 636 K USD
Scanlan Sean F.
Chief Innovation Officer
- 25000
25.4391 USD
1 year ago
Apr 28, 2023
Sell 1 M USD
TREACE JAMES T
Director
- 40000
25.0066 USD
1 year ago
May 01, 2023
Sell 191 K USD
TREACE JAMES T
Director
- 7640
25.037 USD
1 year ago
May 01, 2023
Sell 61.1 K USD
TREACE JAMES T
Director
- 2360
25.9103 USD
1 year ago
Apr 26, 2023
Sell 414 K USD
BAYS F BARRY
Director
- 16204
25.55 USD
1 year ago
Apr 27, 2023
Sell 294 K USD
BAYS F BARRY
Director
- 11600
25.3475 USD
1 year ago
Apr 11, 2023
Sell 1.18 M USD
BAYS F BARRY
Director
- 44764
26.2775 USD
1 year ago
Apr 11, 2023
Sell 137 K USD
BAYS F BARRY
Director
- 5026
27.2798 USD
1 year ago
Apr 12, 2023
Sell 950 K USD
BAYS F BARRY
Director
- 36370
26.1233 USD
1 year ago
Apr 06, 2023
Sell 105 K USD
MOTT RICHARD W
Director
- 4043
26.0008 USD
1 year ago
Apr 03, 2023
Sell 5.23 K USD
MOTT RICHARD W
Director
- 201
26 USD
1 year ago
Apr 04, 2023
Sell 410 K USD
MOTT RICHARD W
Director
- 15756
26.0007 USD
1 year ago
Mar 30, 2023
Sell 1 M USD
MOTT RICHARD W
Director
- 38498
26.0013 USD
1 year ago
Mar 31, 2023
Sell 2.41 M USD
MOTT RICHARD W
Director
- 95000
25.3582 USD
1 year ago
Mar 30, 2023
Sell 1.29 M USD
TREACE JAMES T
Director
- 50000
25.8634 USD
1 year ago
Mar 28, 2023
Sell 657 K USD
BAYS F BARRY
Director
- 26241
25.0238 USD
1 year ago
Mar 29, 2023
Sell 820 K USD
BAYS F BARRY
Director
- 32457
25.2773 USD
1 year ago
Mar 15, 2023
Sell 143 K USD
Owens Daniel E.
- 6250
22.8729 USD
1 year ago
Mar 15, 2023
Sell 1.15 M USD
TIMBIE THOMAS E
Director
- 50000
23.0333 USD
1 year ago
Mar 13, 2023
Sell 200 K USD
BAYS F BARRY
Director
- 8320
24.0731 USD
1 year ago
Mar 13, 2023
Sell 26.7 K USD
BAYS F BARRY
Director
- 1080
24.7305 USD
1 year ago
Mar 14, 2023
Sell 219 K USD
BAYS F BARRY
Director
- 9400
23.2482 USD
1 year ago
Mar 09, 2023
Sell 50.7 K USD
Treace John T.
Chief Executive Offer
- 2075
24.41 USD
1 year ago
Mar 09, 2023
Sell 17.9 K USD
Berutti Aaron
Sr. VP, Sales
- 733
24.41 USD
1 year ago
Mar 09, 2023
Sell 25.4 K USD
Hair Mark
Chief Financial Officer
- 1040
24.41 USD
1 year ago
Mar 09, 2023
Sell 10 K USD
Owens Daniel E.
- 411
24.41 USD
1 year ago
Mar 09, 2023
Sell 12.3 K USD
Scanlan Sean F.
Chief Innovation Officer
- 505
24.41 USD
1 year ago
Mar 09, 2023
Sell 4.32 K USD
Elder Scot Michael
*See "Remarks"
- 177
24.41 USD
1 year ago
Mar 08, 2023
Sell 562 K USD
MOTT RICHARD W
Director
- 25000
22.5 USD
1 year ago
Mar 08, 2023
Sell 480 K USD
MOTT RICHARD W
Director
- 20000
24.0001 USD
1 year ago
Mar 09, 2023
Sell 39.1 K USD
MOTT RICHARD W
Director
- 1502
26 USD
1 year ago
Mar 01, 2023
Sell 1.07 M USD
MOTT RICHARD W
Director
- 50000
21.3509 USD
1 year ago
Feb 28, 2023
Sell 804 K USD
TREACE JAMES T
Director
- 37316
21.54 USD
1 year ago
Mar 01, 2023
Sell 271 K USD
TREACE JAMES T
Director
- 12684
21.36 USD
1 year ago
Feb 21, 2023
Sell 204 K USD
BAYS F BARRY
Director
- 9400
21.7396 USD
1 year ago
Feb 22, 2023
Sell 207 K USD
BAYS F BARRY
Director
- 9400
21.9718 USD
1 year ago
Feb 15, 2023
Sell 542 K USD
Scanlan Sean F.
Chief Innovation Officer
- 25000
21.6894 USD
1 year ago
Feb 15, 2023
Sell 1.09 M USD
TIMBIE THOMAS E
Director
- 50000
21.707 USD
1 year ago
Feb 07, 2023
Sell 202 K USD
BAYS F BARRY
Director
- 8800
22.9962 USD
1 year ago
Feb 08, 2023
Sell 602 K USD
BAYS F BARRY
Director
- 27731
21.705 USD
1 year ago
Feb 02, 2023
Sell 96.3 K USD
MOTT RICHARD W
Director
- 4011
24 USD
1 year ago
Jan 31, 2023
Sell 277 K USD
TREACE JAMES T
Director
- 11929
23.19 USD
1 year ago
Jan 30, 2023
Sell 649 K USD
TREACE JAMES T
Director
- 28214
22.9957 USD
1 year ago
Jan 30, 2023
Sell 208 K USD
TREACE JAMES T
Director
- 8803
23.6751 USD
1 year ago
Jan 30, 2023
Sell 25.9 K USD
TREACE JAMES T
Director
- 1054
24.5538 USD
1 year ago
Jan 30, 2023
Sell 1.41 M USD
MOTT RICHARD W
Director
- 61528
22.9237 USD
1 year ago
Jan 30, 2023
Sell 655 K USD
MOTT RICHARD W
Director
- 27422
23.8714 USD
1 year ago
Jan 30, 2023
Sell 50.1 K USD
MOTT RICHARD W
Director
- 2039
24.5809 USD
1 year ago
Jan 24, 2023
Sell 675 K USD
BAYS F BARRY
Director
- 25921
26.0308 USD
1 year ago
Jan 25, 2023
Sell 517 K USD
BAYS F BARRY
Director
- 20467
25.2817 USD
1 year ago
Jan 25, 2023
Sell 187 K USD
BAYS F BARRY
Director
- 7255
25.7283 USD
1 year ago
Jan 18, 2023
Sell 1.29 M USD
TIMBIE THOMAS E
Director
- 50000
25.88 USD
1 year ago
Jan 17, 2023
Sell 286 K USD
MOTT RICHARD W
Director
- 11014
26.0012 USD
1 year ago
Jan 12, 2023
Sell 639 K USD
Scanlan Sean F.
Chief Innovation Officer
- 25000
25.5723 USD
1 year ago
Jan 12, 2023
Sell 1.1 M USD
MOTT RICHARD W
Director
- 42467
26.0006 USD
1 year ago
Jan 13, 2023
Sell 169 K USD
MOTT RICHARD W
Director
- 6519
26.0001 USD
1 year ago
Jan 11, 2023
Sell 236 K USD
BAYS F BARRY
Director
- 9719
24.32 USD
1 year ago
Jan 12, 2023
Sell 596 K USD
BAYS F BARRY
Director
- 23695
25.1319 USD
1 year ago
Jan 12, 2023
Sell 567 K USD
BAYS F BARRY
Director
- 21841
25.9438 USD
1 year ago
Jan 05, 2023
Sell 229 K USD
MOTT RICHARD W
Director
- 9556
24.002 USD
1 year ago
Jan 09, 2023
Sell 251 K USD
MOTT RICHARD W
Director
- 10444
24.002 USD
1 year ago
Dec 30, 2022
Sell 1.7 M USD
MOTT RICHARD W
Director
- 75000
22.6723 USD
1 year ago
Dec 19, 2022
Sell 207 K USD
BAYS F BARRY
Director
- 9067
22.8592 USD
1 year ago
Dec 20, 2022
Sell 219 K USD
BAYS F BARRY
Director
- 9414
23.2395 USD
1 year ago
Dec 14, 2022
Sell 1.2 M USD
TIMBIE THOMAS E
Director
- 50000
23.9987 USD
1 year ago
Dec 12, 2022
Sell 605 K USD
TREACE JAMES T
Director
- 25000
24.183 USD
1 year ago
Dec 07, 2022
Sell 217 K USD
BAYS F BARRY
Director
- 9061
23.97 USD
1 year ago
Dec 08, 2022
Sell 234 K USD
BAYS F BARRY
Director
- 9739
23.99 USD
1 year ago
Nov 30, 2022
Sell 1.64 M USD
MOTT RICHARD W
Director
- 75000
21.904 USD
1 year ago
Dec 01, 2022
Sell 480 K USD
MOTT RICHARD W
Director
- 20000
24 USD
1 year ago
Dec 02, 2022
Sell 46.9 K USD
Owens Daniel E.
Chief Human Resources Officer
- 1875
25 USD
1 year ago
Nov 28, 2022
Sell 208 K USD
BAYS F BARRY
Director
- 9400
22.092 USD
1 year ago
Nov 29, 2022
Sell 208 K USD
BAYS F BARRY
Director
- 9400
22.177 USD
2 years ago
Nov 18, 2022
Sell 852 K USD
TIMBIE THOMAS E
Director
- 37605
22.659 USD
2 years ago
Nov 18, 2022
Sell 49.3 K USD
TIMBIE THOMAS E
Director
- 2101
23.455 USD
1 year ago
Nov 21, 2022
Sell 4.95 K USD
TIMBIE THOMAS E
Director
- 224
22.084 USD
1 year ago
Nov 22, 2022
Sell 223 K USD
TIMBIE THOMAS E
Director
- 10070
22.105 USD
1 year ago
Nov 21, 2022
Bought 39.9 K USD
Berutti Aaron
Sr. VP, Sales
+ 1825
21.8599 USD
1 year ago
Nov 21, 2022
Bought 327 K USD
Treace John T.
Chief Executive Offer
+ 15000
21.827 USD
2 years ago
Nov 16, 2022
Sell 1.01 M USD
TIMBIE THOMAS E
Director
- 50000
20.138 USD
2 years ago
Nov 17, 2022
Bought 80.2 K USD
Elder Scot Michael
*See "Remarks"
+ 3736
21.4753 USD
2 years ago
Nov 15, 2022
Sell 127 K USD
Owens Daniel E.
Chief Human Resources Officer
- 6250
20.3794 USD
2 years ago
Nov 17, 2022
Bought 217 K USD
Treace John T.
Chief Executive Offer
+ 10000
21.6714 USD
2 years ago
Nov 14, 2022
Sell 607 K USD
Scanlan Sean F.
SVP, Marketing
- 25000
24.2672 USD
2 years ago
Nov 09, 2022
Sell 85.2 K USD
BAYS F BARRY
Director
- 4100
20.77 USD
2 years ago
Nov 09, 2022
Sell 276 K USD
BAYS F BARRY
Director
- 13023
21.19 USD
2 years ago
Nov 10, 2022
Sell 33.7 K USD
BAYS F BARRY
Director
- 1500
22.48 USD
2 years ago
Nov 10, 2022
Sell 187 K USD
BAYS F BARRY
Director
- 7900
23.62 USD
2 years ago
Oct 26, 2022
Sell 14.4 K USD
Elder Scot Michael
*See "Remarks"
- 613
23.46 USD
2 years ago
Oct 31, 2022
Sell 2.24 M USD
MOTT RICHARD W
Director
- 95000
23.5677 USD
2 years ago
Oct 19, 2022
Sell 687 K USD
TREACE JAMES T
Director
- 30397
22.5917 USD
2 years ago
Oct 19, 2022
Sell 254 K USD
TREACE JAMES T
Director
- 10861
23.3739 USD
2 years ago
Oct 20, 2022
Sell 201 K USD
TREACE JAMES T
Director
- 8742
23.0194 USD
2 years ago
Oct 18, 2022
Sell 611 K USD
BAYS F BARRY
Director
- 25428
24.02 USD
2 years ago
Oct 19, 2022
Sell 583 K USD
BAYS F BARRY
Director
- 25647
22.73 USD
2 years ago
Oct 19, 2022
Sell 14.5 K USD
BAYS F BARRY
Director
- 615
23.5 USD
2 years ago
Oct 05, 2022
Sell 367 K USD
BAYS F BARRY
Director
- 16274
22.568 USD
2 years ago
Oct 06, 2022
Sell 313 K USD
BAYS F BARRY
Director
- 13500
23.189 USD
2 years ago
Sep 01, 2022
Sell 30.1 K USD
Owens Daniel E.
Chief Human Resources Officer
- 1500
20.04 USD
2 years ago
Sep 01, 2022
Bought 198 K USD
Treace John T.
Chief Executive Offer
+ 10000
19.8031 USD
2 years ago
Aug 29, 2022
Sell 76.6 K USD
BAYS F BARRY
director:
- 3800
20.15 USD
2 years ago
Aug 26, 2022
Bought 450 K USD
Treace John T.
Chief Executive Offer
+ 21491
20.9549 USD
2 years ago
Aug 23, 2022
Bought 9.63 K USD
Treace John T.
Chief Executive Offer
+ 509
18.9232 USD
2 years ago
Aug 17, 2022
Sell 650 K USD
TREACE JAMES T
director:
- 34046
19.09 USD
2 years ago
Aug 16, 2022
Sell 996 K USD
TIMBIE THOMAS E
director:
- 50000
19.91 USD
2 years ago
Aug 15, 2022
Sell 30 K USD
Owens Daniel E.
Chief Human Resources Officer
- 1500
20 USD
2 years ago
Aug 03, 2022
Sell 895 K USD
TIMBIE THOMAS E
director:
- 48217
18.5562 USD
2 years ago
Aug 01, 2022
Sell 16.9 K USD
Owens Daniel E.
Chief Human Resources Officer
- 1000
16.8904 USD
2 years ago
Jul 18, 2022
Sell 208 K USD
TREACE JAMES T
director:
- 12978
16.058 USD
2 years ago
Jul 13, 2022
Sell 137 K USD
TREACE JAMES T
director:
- 8456
16.1813 USD
2 years ago
Jul 05, 2022
Sell 15 K USD
Owens Daniel E.
Chief HR Officer
- 1000
15 USD
2 years ago
Jun 16, 2022
Sell 283 K USD
TREACE JAMES T
director:
- 20809
13.5794 USD
2 years ago
Jun 01, 2022
Sell 16.7 K USD
Owens Daniel E.
Chief HR Officer
- 1000
16.67 USD
2 years ago
May 25, 2022
Sell 311 K USD
TREACE JAMES T
director:
- 19687
15.7736 USD
2 years ago
May 09, 2022
Sell 16 K USD
Owens Daniel E.
Chief HR Officer
- 1000
15.96 USD
2 years ago
May 09, 2022
Sell 280 K USD
TREACE JOHN R
director:
- 18415
15.2157 USD
2 years ago
Mar 10, 2022
Sell 38.4 USD
TREACE JAMES T
Director
- 2
19.205 USD
2 years ago
Mar 08, 2022
Bought 46.5 K USD
Lubben Terry W.
SVP, Operations
+ 2500
18.6199 USD
2 years ago
Mar 02, 2022
Sell 521 K USD
Scanlan Sean F.
SVP, Marketing
- 25000
20.822 USD
2 years ago
Feb 09, 2022
Sell 78.1 K USD
Scanlan Sean F.
SVP, Marketing
- 3873
20.1605 USD
2 years ago
Feb 08, 2022
Sell 423 K USD
Scanlan Sean F.
SVP, Marketing
- 21127
20.0165 USD
2 years ago
Jan 18, 2022
Sell 700 K USD
TREACE JAMES T
Director
- 36144
19.358 USD
2 years ago
Jan 18, 2022
Sell 136 K USD
TREACE JAMES T
Director
- 6793
20.0048 USD
2 years ago
Jan 19, 2022
Sell 609 K USD
TREACE JAMES T
Director
- 32063
18.9927 USD
2 years ago
Jan 11, 2022
Sell 178 K USD
Scanlan Sean F.
SVP, Marketing
- 8838
20.1229 USD
2 years ago
Jan 10, 2022
Sell 784 K USD
Scanlan Sean F.
SVP, Marketing
- 38862
20.1619 USD
2 years ago
Jan 05, 2022
Sell 16 K USD
Scanlan Sean F.
SVP, Marketing
- 800
20.0225 USD
2 years ago
Jan 04, 2022
Sell 10 K USD
Scanlan Sean F.
SVP, Marketing
- 500
20 USD
2 years ago
Jan 03, 2022
Sell 20 K USD
Scanlan Sean F.
SVP, Marketing
- 1000
20.021 USD
2 years ago
Dec 28, 2021
Sell 336 K USD
Treace John T.
Chief Executive Officer
- 19760
16.9941 USD
2 years ago
Dec 29, 2021
Sell 52.3 K USD
Treace John T.
Chief Executive Officer
- 3075
17.013 USD
2 years ago
Dec 28, 2021
Sell 26.4 K USD
TREACE JAMES T
Director
- 1563
16.8821 USD
2 years ago
Dec 22, 2021
Sell 679 K USD
Treace John T.
Chief Executive Officer
- 41710
16.2876 USD
2 years ago
Dec 23, 2021
Sell 387 K USD
Treace John T.
Chief Executive Officer
- 22795
16.9573 USD
2 years ago
Dec 27, 2021
Sell 299 K USD
Treace John T.
Chief Executive Officer
- 17165
17.4409 USD
2 years ago
Dec 22, 2021
Sell 381 K USD
TREACE JAMES T
Director
- 23390
16.2764 USD
2 years ago
Dec 23, 2021
Sell 213 K USD
TREACE JAMES T
Director
- 12610
16.904 USD
2 years ago
Dec 27, 2021
Sell 112 K USD
TREACE JAMES T
Director
- 6437
17.4581 USD
2 years ago
Dec 20, 2021
Sell 351 K USD
Treace John T.
Chief Executive Officer
- 22311
15.7372 USD
2 years ago
Dec 20, 2021
Sell 9.78 K USD
Treace John T.
Chief Executive Officer
- 600
16.3067 USD
2 years ago
Dec 21, 2021
Sell 548 K USD
Treace John T.
Chief Executive Officer
- 34047
16.0851 USD
2 years ago
Dec 21, 2021
Sell 57.9 K USD
Treace John T.
Chief Executive Officer
- 3537
16.3681 USD
2 years ago
Dec 20, 2021
Sell 247 K USD
TREACE JAMES T
Director
- 15719
15.6872 USD
2 years ago
Dec 20, 2021
Sell 6.52 K USD
TREACE JAMES T
Director
- 400
16.2988 USD
2 years ago
Dec 21, 2021
Sell 217 K USD
TREACE JAMES T
Director
- 13478
16.1215 USD
2 years ago
Dec 21, 2021
Sell 23 K USD
TREACE JAMES T
Director
- 1403
16.3597 USD
2 years ago
Dec 15, 2021
Sell 1.2 M USD
TREACE JAMES T
Director
- 74526
16.0568 USD
2 years ago
Dec 15, 2021
Sell 7.99 K USD
TREACE JAMES T
Director
- 474
16.8643 USD
2 years ago
Nov 22, 2021
Sell 293 K USD
TREACE JAMES T
Director
- 15854
18.51 USD
2 years ago
Nov 22, 2021
Sell 2.83 K USD
TREACE JAMES T
Director
- 146
19.39 USD
2 years ago
Nov 23, 2021
Sell 265 K USD
TREACE JAMES T
Director
- 15264
17.3695 USD
2 years ago
Nov 23, 2021
Sell 32 K USD
TREACE JAMES T
Director
- 1736
18.41 USD
2 years ago
Nov 24, 2021
Sell 303 K USD
TREACE JAMES T
Director
- 17000
17.8257 USD
2 years ago
Nov 22, 2021
Sell 960 K USD
Treace John T.
Chief Executive Officer
- 52354
18.34 USD
2 years ago
Nov 22, 2021
Sell 12.3 K USD
Treace John T.
Chief Executive Officer
- 646
19.11 USD
2 years ago
Nov 23, 2021
Sell 926 K USD
Treace John T.
Chief Executive Officer
- 53275
17.3747 USD
2 years ago
Nov 23, 2021
Sell 49 K USD
Treace John T.
Chief Executive Officer
- 2725
18 USD
2 years ago
Nov 24, 2021
Sell 455 K USD
Treace John T.
Chief Executive Officer
- 25743
17.6632 USD
2 years ago
Nov 24, 2021
Sell 545 K USD
Treace John T.
Chief Executive Officer
- 30257
17.9985 USD
3 years ago
Nov 15, 2021
Sell 398 K USD
TREACE JAMES T
Director
- 19485
20.41 USD
3 years ago
Nov 15, 2021
Sell 118 K USD
TREACE JAMES T
Director
- 5515
21.41 USD
3 years ago
Nov 16, 2021
Sell 522 K USD
TREACE JAMES T
Director
- 25000
20.86 USD
3 years ago
Nov 17, 2021
Sell 508 K USD
TREACE JAMES T
Director
- 25000
20.33 USD
3 years ago
Nov 10, 2021
Sell 529 K USD
Scanlan Sean F.
SVP, Marketing
- 24560
21.5254 USD
3 years ago
Nov 10, 2021
Sell 9.77 K USD
Scanlan Sean F.
SVP, Marketing
- 440
22.1981 USD
3 years ago
Oct 20, 2021
Sell 561 K USD
Treace John T.
Chief Executive Officer
- 22612
24.7891 USD
3 years ago
Oct 20, 2021
Sell 208 K USD
Treace John T.
Chief Executive Officer
- 8215
25.3654 USD
3 years ago
Oct 21, 2021
Sell 683 K USD
Treace John T.
Chief Executive Officer
- 34325
19.894 USD
3 years ago
Oct 21, 2021
Sell 552 K USD
Treace John T.
Chief Executive Officer
- 26701
20.6733 USD
3 years ago
Oct 21, 2021
Sell 59.5 K USD
Treace John T.
Chief Executive Officer
- 2768
21.4949 USD
3 years ago
Oct 21, 2021
Sell 189 K USD
Treace John T.
Chief Executive Officer
- 8207
23.0705 USD
3 years ago
Oct 21, 2021
Sell 96.5 K USD
Treace John T.
Chief Executive Officer
- 4044
23.8552 USD
3 years ago
Oct 21, 2021
Sell 956 USD
Treace John T.
Chief Executive Officer
- 39
24.5 USD
3 years ago
Oct 22, 2021
Sell 1.19 M USD
Treace John T.
Chief Executive Officer
- 57534
20.7397 USD
3 years ago
Oct 22, 2021
Sell 11.7 K USD
Treace John T.
Chief Executive Officer
- 555
21.1578 USD
3 years ago
Oct 20, 2021
Sell 281 K USD
TIMBIE THOMAS E
Director
- 11171
25.1763 USD
3 years ago
Oct 01, 2021
Bought 471 K USD
Jain Deepti
Director
+ 17750
26.52 USD
3 years ago
Apr 27, 2021
Sell 89.3 M USD
Treace John T.
Chief Executive Officer
- 5253805
17 USD
3 years ago
Apr 27, 2021
Bought 170 K USD
Hair Mark
Chief Financial Officer
+ 10000
17 USD
3 years ago
Apr 27, 2021
Bought 61.2 K USD
Hair Mark
Chief Financial Officer
+ 3600
17 USD
3 years ago
Apr 27, 2021
Sell 6.82 M USD
TREACE JOHN R
Director
- 401250
17 USD
3 years ago
Apr 27, 2021
Sell 5.6 M USD
Frias Jaime A.
See Remarks
- 329230
17 USD
3 years ago
Apr 27, 2021
Bought 68 K USD
Owens Daniel E.
Chief HR Officer
+ 4000
17 USD
15 years ago
Sep 30, 2009
Sell 0 USD
HARRIS JOHN N
Director
- 100000
0 USD
13 years ago
Nov 24, 2010
Sell 190 K USD
HARRIS JOHN N
Director
- 100000
1.9 USD
15 years ago
Jun 30, 2009
Bought 18 K USD
HARRIS JOHN N
President
+ 180000
0.1 USD
7. News
The Schall Law Firm Invites Shareholder Participation In An Inquiry Into Treace Medical Concepts, Inc. For Securities Law Violations LOS ANGELES, CA / ACCESSWIRE / November 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 1 day ago
Treace Medical Concepts Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Help The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / November 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 2 days ago
The Schall Law Firm Invites Shareholders To Join An Inquiry Into Treace Medical Concepts, Inc. For Securities Law Violations LOS ANGELES, CA / ACCESSWIRE / November 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 3 days ago
Treace Medical Concepts Inc Is Being Investigated For Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / November 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 4 days ago
TMCI Investors Have Opportunity to Join Treace Medical Concepts, Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES , Nov. 12, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ: TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. prnewswire.com - 4 days ago
The Schall Law Firm Wants Shareholders To Join An Inquiry Into Treace Medical Concepts, Inc. For Securities Law Violations LOS ANGELES, CA / ACCESSWIRE / November 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 5 days ago
Treace Medical Concepts Inc May Have Defrauded The Public And Investors With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / November 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 6 days ago
The Schall Law Firm Invites Stockholders To Join An Inquiry Into Treace Medical Concepts, Inc.'s Securities Law Violations LOS ANGELES, CA / ACCESSWIRE / November 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 1 week ago
Treace Medical Concepts Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / November 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 1 week ago
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Treace Medical Concepts, Inc. For Securities Law Violations LOS ANGELES, CA / ACCESSWIRE / November 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 1 week ago
Treace Medical Concepts Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / November 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 1 week ago
Treace Medical Concepts, Inc. (TMCI) Q3 2024 Earnings Call Transcript Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q3 2024 Earnings Call November 5, 2024 4:30 PM ET Company Participants Vivian Cervantes - Investor Relations John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Danielle Antalffy - UBS Operator Good day and thank you for standing by. Welcome to the Treace Medical Concepts Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 1 week ago
8. Profile Summary

Treace Medical Concepts, Inc. TMCI

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 474 M
Dividend Yield 0.00%
Description Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
Contact 203 Fort Wade Road, Ponte Vedra, FL, 32081 https://www.treace.com
IPO Date April 23, 2021
Employees 516
Officers Mr. Scot M. Elder J.D. Chief Legal & Compliance Officer and Corporate Secretary Ms. Shana Zink Senior Vice President of Clinical Affairs & Reimbursement Mr. Terry W. Lubben Chief Operations & Supply Chain Officer Mr. Taylor Erickson Chief Information Officer Mr. Daniel E. Owens Chief Human Resources Officer Mr. Nathan Minnich Senior Vice President of Marketing Dr. Sean F. Scanlan Ph.D. Chief Innovation Officer Mr. John T. Treace Chief Executive Officer, Founder & Director Mr. Mark L. Hair CPA Chief Financial Officer Mr. Aaron J. Berutti Senior Vice President of Sales